Delays the Digestive Process : This medicine delays the passage of food from the stomach to the intestines, thus leading to slow entry of glucose into the blood
BPI Labs is launching a number of 503B injectable products, the lawsuit warned, claiming the facility was built to produce large batches with or without prescriptions. The case settled on May 21, according to PACER
Other At-Risk Groups GLP-1 medications are generally not suitable for individuals with severe gastrointestinal disorders like gastroparesis, those with type 1 diabetes (as these drugs are approved only for type 2 diabetes and obesity), and people with a history of suicidal thoughts, active eating disorders, or heavy alcohol use
Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system